Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYunfei HuYHYunhong Huang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows 84% overall response in marginal zone lymphoma patients treated with orelabrutinib, indicating promising safety and progress-free survival outcomes.

Key Points

  • Overall response rate reached 84% among patients treated with orelabrutinib-based regimens.
  • Progression-free survival data indicated a promising 12-month rate of 94.2% for treated patients.
  • Retrospective cohort study at Guizhou Provincial Cancer Hospital assessed safety and efficacy outcomes.
  • This indicates that orelabrutinib offers a favorable safety profile, especially in chemo-free regimens.

Cite This Study

Hu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d45ahttps://doi.org/10.1182/blood-2025-1817
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  2. 2Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  3. 3Efficacy and safety of orelabrutinib monotherapy in patients with chronic lymphocytic leukemia: A retrospective real-world study2025
  4. 4Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study2025 · 1 citations
  5. 5Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)2025